| Title |
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, February 2015
|
| DOI | 10.1007/s10549-015-3287-5 |
| Pubmed ID | |
| Authors |
Caterina Fontanella, Bianca Lederer, Stephan Gade, Mieke Vanoppen, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann, Bernd Gerber, Claus Hanusch, Jörn Hilfrich, Jens Huober, Andreas Schneeweiss, Stefan Paepke, Christian Jackisch, Keyur Mehta, Valentina Nekljudova, Michael Untch, Patrick Neven, Gunter von Minckwitz, Sibylle Loibl |
| Abstract |
Obesity is associated with an increased risk of breast cancer (BC) and poorer outcome. We assessed the impact of body mass index (BMI) on pathological complete response (pCR), disease-free (DFS), and overall survival (OS), according to BC subtypes in patients with primary BC treated with neoadjuvant chemotherapy. 8,872 patients with primary BC from eight neoadjuvant trials were categorized according to BMI: underweight (<18.5 kg/m(2)), normal weight (18.5 to <25 kg/m(2)), overweight (25 to <30 kg/m(2)), obese (30 to <40 kg/m(2)), and very obese (≥40 kg/m(2)). BC subtypes were defined as luminal-like (ER/PgR-positive and HER2-negative), HER2/luminal (ER/PgR-positive and HER2-positive), HER2-like (ER/PgR-negative and HER2-positive), and triple-negative (TNBC; ER/PgR- and HER2-negative). pCR rate was higher in normal weight patients compared with all other BMI groups (P = 0.003). Mean DFS and OS were shorter in obese (87.3 months, P = 0.014 and 94.9 months, P = 0.001, respectively) and very obese (66.6 months, P < 0.001 and 75.3 months, P < 0.001, respectively) compared with normal weight patients (91.5 and 98.8 months, respectively) which was confirmed by subpopulation treatment effect pattern plot analyses and was consistent in luminal-like and TNBC. No interaction was observed between BMI and pCR. Normal weight patients experienced less non-hematological adverse events (P = 0.002) and were more likely to receive full taxane doses (P < 0.001) compared with all other BMI groups. In multivariable analysis, the dose of taxanes was predictive for pCR (P < 0.001). Higher BMI was associated with lower pCR and a detrimental impact on survival. Normal weight patients had the best compliance to chemotherapy and received the highest taxane doses, which seems to be related with treatment outcomes. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 115 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Croatia | 1 | <1% |
| Portugal | 1 | <1% |
| Unknown | 113 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 19 | 17% |
| Student > Master | 16 | 14% |
| Student > Doctoral Student | 13 | 11% |
| Student > Ph. D. Student | 12 | 10% |
| Student > Bachelor | 8 | 7% |
| Other | 17 | 15% |
| Unknown | 30 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 52 | 45% |
| Nursing and Health Professions | 9 | 8% |
| Biochemistry, Genetics and Molecular Biology | 6 | 5% |
| Agricultural and Biological Sciences | 5 | 4% |
| Computer Science | 2 | 2% |
| Other | 9 | 8% |
| Unknown | 32 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 February 2015.
All research outputs
#17,748,987
of 22,792,160 outputs
Outputs from Breast Cancer Research and Treatment
#3,573
of 4,655 outputs
Outputs of similar age
#246,878
of 358,538 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#45
of 68 outputs
Altmetric has tracked 22,792,160 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,655 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 358,538 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.